Jiangxi Fushine Pharma
It competes as an integrated anti-infective API and intermediate producer spanning carbapenem and penem from starting materials to APIs.
- Public company
It competes as an integrated anti-infective API and intermediate producer spanning carbapenem and penem from starting materials to APIs.
Jiangxi Fushine Pharmaceutical Co’s stock price drops by 2.07% in a single trading session. The decline follows unspecified market conditions or company developments. The company operates in the pharmaceutical sector, though no specific catalysts for the drop are detailed in the report.
Nov 2026Global Banking & Finance ReviewNews article
Jiangxi Fushine Pharmaceutical Co’s stock price increases by 4.50% on Wednesday. The company operates in the pharmaceutical sector, though no specific catalysts for the rise are detailed in the report. The update reflects a single-day market movement without additional context on performance drivers or corporate developments.
Nov 2026Global Banking & Finance ReviewNews article
Jiangxi Fushine Pharmaceutical Co., Ltd. reports **CNY 1.55 billion in sales and revenue** for the nine months ended September 30, 2026, more than doubling the **CNY 769.35 million** recorded in the same period a year prior. The company’s financial performance shows significant year-over-year growth in both revenue and sales figures. No further operational or product-specific details are provided in the earnings report.
Oct 2026MarketScreenerNews article
Jiangxi Fushine Pharmaceutical Co experiences a 4.51% drop in stock value on a single trading day. The decline follows broader market movements affecting pharmaceutical sector stocks. No specific company developments or announcements are cited as the cause of the decrease.
Oct 2026Global Banking & Finance ReviewNews article